keyword
MENU ▼
Read by QxMD icon Read
search

Haplo transplant

keyword
https://www.readbyqxmd.com/read/29155367/predicted-indirectly-recognizable-hla-epitopes-are-not-associated-with-clinical-outcomes-after-haploidentical-hematopoietic-stem-cell-transplantation
#1
Ming-Rui Huo, Dan Li, Ying-Jun Chang, Lan-Ping Xu, Xiao-Hui Zhang, Kai-Yan Liu, Xiao-Jun Huang
Haploidentical stem cell transplantation (haplo-SCT) provides an alternative method to cure patients with malignant and nonmalignant hematologic diseases who lack a human leukocyte antigen (HLA) matched related or unrelated donor. HLA disparity between donor and patient was the main reason causing lots of clinical immune response. The aim of this study was to investigate whether indirect recognition of mismatched HLA could predict the clinical outcomes in haplo-SCT. The probability of indirect recognition was predicted by the Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) model...
November 16, 2017: Human Immunology
https://www.readbyqxmd.com/read/29132903/progressive-multifocal-leukoencephalopathy-in-patients-receiving-rituximab-and-cyclophosphamide-after-haplo-identical-t-cell-replete-transplantation-and-review-of-the-literature
#2
REVIEW
R Salem, R Massoud, S S Kanj, M Hamdan, R Salman, A Bazarbachi, J El-Cheikh
John Cunningham virus (JCV) reactivation, occurring mainly in immunocompromised patients, leads to progressive multifocal leukoencephalopathy, an uncommon but lethal disease. JCV reactivation after T-cell replete haploidentical stem cell transplantation, in the pre-cyclophosphamide era, is poorly represented in the literature. We therefore describe two cases of acute myeloid leukemia who developed JCV reactivation after receiving cyclophosphamide and rituximab post haploidentical stem cell transplantation, and review the literature, aiming to a better understanding of the disease course and its risk factors...
November 10, 2017: Current Research in Translational Medicine
https://www.readbyqxmd.com/read/29128555/combined-haploidentical-and-umbilical-cord-blood-allogeneic-stem-cell-transplantation-for-high-risk-lymphoma-and-cll
#3
Jingmei Hsu, Andrew Artz, Sebastian A Mayer, Danielle Guarner, Michael R Bishop, Ronit Reich-Slotky, Sonali M Smith, June Greenberg, Justin Kline, Rosanna Ferrante, Adrienne A Phillips, Usama Gergis, Hongtao Liu, Wendy Stock, Melissa Cushing, Tsiporah B Shore, Koen van Besien
Limited studies have reported on outcomes for lymphoid malignancy patients receiving alternative donor allogeneic stem cell transplants. We have previously described combining CD34-selected haploidentical grafts with umbilical cord blood (haplo-cord) to accelerate neutrophil and platelet engraftment. Here, we examine the outcome of patients with lymphoid malignancies undergoing haplo-cord transplantation at the University of Chicago and Weill Cornell Medical College. We analyzed 42 lymphoma and CLL patients who underwent haplo-cord allogeneic stem cell transplantation...
November 8, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29114918/donor-age-determines-outcome-in-acute-leukemia-patients-over-40-undergoing-haploidentical-hematopoietic-cell-transplantation
#4
Jonathan Canaani, Bipin N Savani, Myriam Labopin, Xiao-Jun Huang, Fabio Ciceri, William Arcese, Yener Koc, Johanna Tischer, Didier Blaise, Zafer Gülbas, Maria Teresa Van Lint, Benedetto Bruno, Mohamad Mohty, Arnon Nagler
Haploidentical hematopoietic cell transplantation (haplo-HCT) is being increasingly used in acute leukemia patients as an alternative transplant modality when matched sibling or matched unrelated donors are unavailable. As several potential haploidentical relative donors are typically available for a given patient, optimizing donor selection to improve clinical outcome is crucial. The impact of donor age and kinship on the outcome of acute leukemia patients is not clearly established in this setting. Using the multinational registry of the acute leukemia working party of the European society for blood and marrow transplantation we retrospective analyzed the clinical outcome of 1270 acute myeloid leukemia and acute lymphoblastic leukemia patients who underwent haplo-HCT between 2005 and 2015...
November 8, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/29084206/myeloablative-conditioning-regimens-with-combined-of-haploidentical-and-cord-blood-transplantation-for-myelodysplastic-syndrome-patients
#5
P Ke, X-B Bao, X-H Hu, J Zhuang, X-J Wu, Y-J Liu, X-F He, D-P Wu, S-L Xue, X Ma
The purpose of this study was to evaluate the strategy of haploidentical (HID) stem cell combined with a small doses of umbilical cord blood (UCB) from a third-party donor transplantation (haplo-cord transplant) for treatment of myelodysplastic syndromes (MDS), by comparing with identical-sibling donor (ISD) transplantation. Eighty-five patients were included between January 2012 and December 2015, with a median 40 years old. Forty-eight patients received haplo-cord transplant and 37 patients received ISD transplant...
October 30, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/29076142/donor-derived-cd19-targeted-t-cell-infusion-induces-minimal-residual-disease-negative-remission-in-relapsed-b-cell-acute-lymphoblastic-leukaemia-with-no-response-to-donor-lymphocyte-infusions-after-haploidentical-haematopoietic-stem-cell-transplantation
#6
Yuhong Chen, Yifei Cheng, Pan Suo, Chenhua Yan, Yu Wang, Yao Chen, Wei Han, Lanping Xu, Xiaohui Zhang, Kaiyan Liu, Lungji Chang, Lei Xiao, Xiaojun Huang
Relapse is a common cause of failure in patients with B-cell acute lymphoblastic leukaemia (B-ALL) after haploidentical haematopoietic stem cell transplantation (haplo-HSCT), and non-responders to donor lymphoblastic infusion after HSCT have a very poor prognosis. Although donor-derived CD19-directed chimeric antigen receptor-modified (CAR) T cells can potentially cure leukaemia, their effectiveness and safety have not been confirmed in relapsed B-ALL cases after haplo-HSCT. Between January 2015 and January 2017, two and four patients each received one and two infusions of CAR T cells from haplo-HSCT donors...
October 26, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/29070137/-clinical-study-on-treatment-of-juvenile-myelomonocytic-leukemia-with-haploidentical-hematopoietic-stem-cell-transplantation
#7
Li Ding, Heng Zhu, Dong-Mei Han, Zhi-Dong Wang, Xiao-Li Zheng, Lei Dong, Hong-Min Yan, Jing Liu, Ling Zhu, Mei Xue, Zi-Kuan Guo, Heng-Xiang Wang
OBJECTIVE: To analyze the therapeutic efficacy of haploidentical-hematopoietic stem cell transplantation (hi-HSCT) for patients with juvenile myelomonocytic leukemia (JMML). METHODS: The engraftment of hematopoietic stem cells, incidence of graft versus host disease (GVHD), infection, relapse, and survival of 6 JMML patients received hi-HSCT were retrospectively analyzed. RESULTS: Six (6 males) JMML patients received hi-HSCT from haplo-HLA-matched related donors...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29055682/grade-ii-acute-graft-versus-host-disease-and-higher-nucleated-cell-graft-dose-improve-progression-free-survival-after-hla-haploidentical-transplant-with-post-transplant-cyclophosphamide
#8
Shannon R McCurdy, Christopher G Kanakry, Hua-Ling Tsai, Yvette L Kasamon, Margaret M Showel, Javier Bolaños-Meade, Carol Ann Huff, Ivan Borrello, William H Matsui, Robert A Brodsky, Richard F Ambinder, Maria P Bettinotti, Ephraim J Fuchs, Gary L Rosner, Richard J Jones, Leo Luznik
Compared with standard graft-versus-host disease (GVHD) prophylaxis platforms, post-transplantation cyclophosphamide (PTCy) after T cell-replete HLA-haploidentical (haplo) bone marrow transplantation (BMT) reduces the risk of grades III to IV acute (a) and chronic (c) GVHD but maintains similar rates of grade II aGVHD. Given that mild GVHD has been associated with reduced treatment failure in HLA-matched BMT, we evaluated the risk factors for and effects of GVHD on survival in 340 adults with hematologic malignancies who engrafted after nonmyeloablative haplo-BMT with PTCy, mycophenolate mofetil, and tacrolimus...
October 18, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29029297/cytomegalovirus-specific-t-cell-transfer-for-refractory-cytomegalovirus-infection-after-haploidentical-stem-cell-transplantation-the-quantitative-and-qualitative-immune-recovery-for-cytomegalovirus
#9
Xu-Ying Pei, Xiang-Yu Zhao, Ying-Jun Chang, Jing Liu, Lan-Ping Xu, Yu Wang, Xiao-Hui Zhang, Wei Han, Yu-Hong Chen, Xiao-Jun Huang
Background: The efficiency and mechanisms of adoptive transfer of cytomegalovirus (CMV)specific T cells for refractory CMV infection after haploidentical stem cell transplantation (haplo-SCT) remain largely unknown. Methods: Thirty-two patients with refractory CMV infection who accepted treatment with adoptive CMV-specific T-cell infusion following haplo-SCT were prospectively enrolled. Another 32 patients with nonrefractory CMV infection after haplo-SCT were selected as control subjects...
November 15, 2017: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/29024804/impact-of-hla-disparity-in-haploidentical-bone-marrow-transplantation-followed-by-high-dose-cyclophosphamide
#10
Anna Maria Raiola, Antonio Risitano, Nicoletta Sacchi, Livia Giannoni, Alessio Signori, Sara Aquino, Stefania Bregante, Carmen Di Grazia, Alida Dominietto, Simona Geroldi, Anna Ghiso, Francesca Gualandi, Teresa Lamparelli, Elisabetta Tedone, Maria Teresa Van Lint, Riccardo Varaldo, Adalberto Ibatici, Carlo Marani, Serena Marotta, Fabio Guolo, Daniele Avenoso, Lucia Garbarino, Fabrizio Pane, Andrea Bacigalupo, Emanuele Angelucci
We studied the impact of HLA mismatching on the outcome of 318 consecutive patients who received an unmanipulated haploidentical bone marrow transplant, followed by post-transplant cyclophosphamide (PTCy). The number of HLA-mismatched antigens was tested for its impact on overall survival (OS) and nonrelapse mortality (NRM), whereas HLA mismatches in the graft-versus-host (GVH) direction were tested for prediction of graft-versus-host disease (GVHD and relapse. Finally, we studied whether graft rejection correlated with the number of HLA mismatched antigens in host-versus-graft (HVG) direction...
October 9, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28988422/comparison-of-two-cytoreductive-regimens-for-%C3%AE-%C3%AE-t-cell-depleted-haploidentical-hsct-in-pediatric-malignancies-improved-engraftment-and-outcome-with-tbi-based-regimen
#11
Elad Jacoby, Nira Varda-Bloom, Gal Goldstein, Daphna Hutt, Chaim Churi, Helly Vernitsky, Amos Toren, Bella Bielorai
BACKGROUND: Graft manipulation using selective depletion of αβ-T cells provides a source of haploidentical hematopoietic stem cell transplantation (haplo-HSCT) enriched in effector cells. We report our experience implementing this haplo-HSCT for high-risk malignancies in pediatric patients focusing on the conditioning regimen. PROCEDURE: We performed a retrospective study of patients who underwent T-cell receptor αβ-depleted haplo-HSCT for high-risk pediatric malignancies...
October 8, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28986344/nk-cell-recovery-after-haploidentical-hsct-with-post-transplant-cyclophosphamide-dynamics-and-clinical-implications
#12
Antonio Russo, Giacomo Oliveira, Sofia Berglund, Raffaella Greco, Valentina Gambacorta, Nicoletta Cieri, Cristina Toffalori, Laura Zito, Francesca Lorentino, Simona Piemontese, Mara Morelli, Fabio Giglio, Andrea Assanelli, Maria Teresa Lupo Stanghellini, Chiara Bonini, Jacopo Peccatori, Fabio Ciceri, Leo Luznik, Luca Vago
The use of post-transplant cyclophosphamide (PT-Cy) as GvHD prophylaxis has revolutionized haploidentical HSCT, allowing safe infusion of unmanipulated T cell-replete grafts. PT-Cy selectively eliminates proliferating alloreactive T cells, but whether and how it affects NK cells and their alloreactivity is largely unknown. Here we characterized NK cell dynamics in 17 patients who received unmanipulated haploidentical grafts, containing high numbers of mature NK cells, according to PT-Cy-based protocols in two independent centers...
October 6, 2017: Blood
https://www.readbyqxmd.com/read/28971493/tocilizumab-for-severe-cytokine-release-syndrome-after-haploidentical-donor-transplantation-in-a-patient-with-refractory-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma
#13
Hiroshi Ureshino, Toshihiko Ando, Haruna Kizuka, Kana Kusaba, Haruhiko Sano, Atsujiro Nishioka, Hidekazu Itamura, Takero Shindo, Yasushi Kubota, Kensuke Kojima, Shinya Kimura
It has been well documented that patients may develop cytokine-release syndrome (CRS) following the administration of monoclonal antibodies, such as chimeric antigen receptor-modified T cell. Cytokine-release syndrome is a common complication in patients who have received haploidentical donor allogeneic haematopoietic cell transplantation (haplo-HCT). Although severe CRS after haplo-HCT is a potentially life-threatening toxicity, a standard treatment has not been established. Cytokine blockade with tocilizumab, an anti-IL-6 receptor antibody, has been effective for the treatment of patients with CRS after chimeric antigen receptor-modified T-cell treatment and has also improved CRS after haplo-HCT...
October 3, 2017: Hematological Oncology
https://www.readbyqxmd.com/read/28969012/similar-outcomes-after-haploidentical-transplantation-with-post-transplant-cyclophosphamide-versus-hla-matched-transplantation-a-meta-analysis-of-case-control-studies
#14
Zhenyang Gu, Li Wang, Lei Yuan, Wenrong Huang, Meng Li, Lixun Guan, Qingyi Wang, Zhe Gao, Shasha Zhao, Lan Luo, Feiyan Wang, Nan Yang, Daihong Liu, Jon C Aster, Chunji Gao
BACKGROUND: Outcomes of haploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplant cyclophosphamide (PT-Cy) have greatly improved. It remains unknown whether haplo-HCT with PT-Cy was associated with poor outcomes when compared with HLA-matched HCT. To address this issue, we performed a meta-analysis to compare outcomes of haplo-HCT with PT-Cy with those of HLA-matched HCT. METHODS: A systematic search for case-control studies were performed in PubMed, Embase and Cochrane Library databases...
September 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28958289/maximizing-the-benefit-of-allogeneic-stem-cell-transplantation-in-myelodysplastic-syndromes
#15
REVIEW
Nicolaus Kröger
Allogeneic stem cell transplantation (AHSCT) is an evolving field in the treatment of patients with myelodysplastic syndrome (MDS) and has become the third most frequent indication for AHSCT worldwide. Less toxic conditioning regimens, as well as extension of the donor pool to include haplo-identical donors, have led to a broader utility of AHSCT, especially in older patients with MDS. While disease-specific scoring systems such as the International Prognostic Scoring System (IPSS), IPSS-Revised (IPSS-R), or World Health Organization (WHO) Prognostic Scoring System (WPSS) have been used to select patients for AHSCT, new transplant-specific scoring systems have been developed to determine outcome after AHSCT, which include also transplant- and patient-related factors that determine more precisely outcome and allows to balance more properly the risk of relapse and non-relapse mortality...
July 2017: Seminars in Hematology
https://www.readbyqxmd.com/read/28914433/platelet-transfusion-refractoriness-after-t-cell-replete-haploidentical-transplantation-is-associated-with-inferior-clinical-outcomes
#16
Qiang Fu, Lanping Xu, Xiaohui Zhang, Yu Wang, Yingjun Chang, Kaiyan Liu, Xiaojun Huang
Haploidentical stem cell transplantation (haplo-SCT) has been an alternative source of bone marrow for patients without human leukocyte antigen (HLA)-matched donors. The aim of this study was to investigate the relationships between platelet transfusion refractoriness (PTR) and clinical outcomes in the setting of haplo-SCT. Between May 2012 and March 2014, 345 patients who underwent unmanipulated haplo-SCT were retrospectively enrolled. PTR occurred in 20.6% of all patients. Patients in the PTR group experienced higher transplant-related mortality (TRM, 43...
September 13, 2017: Science China. Life Sciences
https://www.readbyqxmd.com/read/28877042/hematopoietic-cell-transplantation-for-aplastic-anemia
#17
Rajat Kumar, Carmem Bonfim, Biju George
PURPOSE OF REVIEW: Improvements in allogeneic hematopoietic cell transplantation (HCT) with better donor selection, conditioning regimens and graft vs. host disease prophylaxis make it reasonable to move HCT earlier in the algorithm for management of severe aplastic anemia (SAA). Recent progress in transplantation is reviewed whereas issues related to developing countries are also addressed. RECENT FINDINGS: Multiple research centers are reporting on clonality, mutations and telomere disorders in SAA, which may help to choose the most appropriate therapy upfront...
November 2017: Current Opinion in Hematology
https://www.readbyqxmd.com/read/28865971/haploidentical-hematopoietic-stem-cell-transplantation-for-myelodysplastic-syndrome
#18
Xiao-Dong Mo, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Kai-Yan Liu, Xiao-Jun Huang
This study aimed to validate the capability of the Center for International Blood and Marrow Transplant Research (CIBMTR) prognostic scoring system to predict outcomes of patients with myelodysplastic syndromes (MDS) who had undergone HLA-haploidentical related donor hematopoietic stem cell transplantation (haplo-HSCT). We also propose and validate a more suitable prognostic scoring system. A total of 157 patients with MDS who underwent haplo-HSCT were enrolled. The CIBMTR prognostic scoring system could predict the 2-year clinical outcomes, but failed to predict the 100-day clinical outcomes after haplo-HSCT...
September 1, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28865164/viral-specific-t-cell-response-in-hemorrhagic-cystitis-after-haploidentical-donor-stem-cell-transplantation
#19
Nopporn Apiwattanakul, Suradej Hongeng, Usanarat Anurathapan, Samart Pakakasama, Supanart Srisala, Chonnamet Techasaensiri, Borje S Andersson
Viral hemorrhagic cystitis (HC) after hematopoietic stem cell transplantation (HSCT) can be devastating. Standard treatment modalities have not been well established, but immune reconstitution may be necessary for sustained viral clearance. We studied five pediatric patients who developed viral HC after haplo-identical HSCT. All patients developed virus-specific CD4- and CD8-positive T cells, and the emergence of these viral-specific T cells was temporally associated with successful viral clearance. This article is protected by copyright...
September 2, 2017: Transplant Infectious Disease: An Official Journal of the Transplantation Society
https://www.readbyqxmd.com/read/28846465/post-transplantation-cyclophosphamide-based-haploidentical-transplantation-as-alternative-to-matched-sibling-or-unrelated-donor-transplantation-for-hodgkin-lymphoma-a-registry-study-of-the-lymphoma-working-party-of-the-european-society-for-blood-and-marrow
#20
Carmen Martínez, Jorge Gayoso, Carmen Canals, Hervé Finel, Karl Peggs, Alida Dominietto, Luca Castagna, Boris Afanasyev, Stephen Robinson, Didier Blaise, Paolo Corradini, Maija Itälä-Remes, Arancha Bermúdez, Edouard Forcade, Domenico Russo, Michael Potter, Grant McQuaker, Ibrahim Yakoub-Agha, Christof Scheid, Adrian Bloor, Silvia Montoto, Peter Dreger, Anna Sureda
Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation...
October 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
50971
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"